COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,629 Articles (22,913 medRxiv, 8,716 bioRxiv)

Most recent first Previous |  Page 355: Articles 3541-3550  | Next

Comparative Organ Disease Burden and Sequelae of Influenza and SARS-CoV-2 Infection: An Observational Study Using Real-World Data
Bartha, I., Maher, M. C., Lavrenko, V., Boundy, K., Kinter, E., Yeh, W., Corti, D., Telenti, A.
10.1101/2023.10.26.23297626 — Posted: 2023-10-26
Online trend estimation and detection of trend deviations in sub-sewershed time series of SARS-CoV-2 RNA measured in wastewater.
Ensor, K. B., Schedler, J. C., Sun, T., Schneider, R., Mulenga, A., Wu, J., Stadler, L., Hopkins, L.
10.1101/2023.10.26.23297635 — Posted: 2023-10-26
Integrating population-level and cell-based signatures for drug repositioning
He, C., Xu, Y., Zhou, Y., Fan, J., Cheng, C., Meng, R., Gamazon, E. R., Zhou, D.
10.1101/2023.10.25.564079 — Posted: 2023-10-26
Reduced Monocyte Proportions and Responsiveness in Convalescent COVID-19 Patients
Ravkov, E., Williams, E. S. C. P., Elgort, M., Spivak, A., Barker, A. P., Planelles, V., Delgado, J., Lin, L., Hanley, T.
10.1101/2023.10.25.563806 — Posted: 2023-10-26
A deep learning framework for predicting the neutralizing activity of COVID-19 therapeutics and vaccines against evolving SARS-CoV-2 variants
Matson, R. P., Comba, I. Y., Silvert, E., Niesen, M. J., Murugadoss, K., Padwardhan, D., Suratekar, R., Goel, E.-G., Poelaert, B. J., Wan, K., Brimacombe, K. R., Venkatakrishnan, A., Soundararajan, V.
10.1101/2023.10.24.563847 — Posted: 2023-10-26
Early antiviral CD4 and CD8 T cell responses are associated with upper respiratory tract clearance of SARS-CoV-2
Ramirez, S. I., Lopez, P. G., Faraji, F., Parikh, U. M., Heaps, A., Ritz, J., Moser, C., Eron, J. J., Wohl, D. A., Currier, J. S., Daar, E. S., Greninger, A. L., Klekotka, P., Grifoni, A., Weiskopf, D., Sette, A., Peters, B., Hughes, M. D., Chew, K. W., Smith, D. M., Crotty, S., ACTIV-2/A5401 Study Team
10.1101/2023.10.25.564014 — Posted: 2023-10-26
Discovery of a novel inhibitor of macropinocytosis with antiviral activity
Porebski, B., Christ, W., Corman, A., Haraldsson, M., Barz, M., Lidemalm, L., Haggblad, M., Illmain, J., Wright, S., Murga, M., Schlegel, J., Sezgin, E., Bhabha, G., Lauschke, V. M., Lafarga, M., Klingstrom, J., Huhn, D., Fernandez-Capetillo, O.
10.1101/2023.10.25.563967 — Posted: 2023-10-26
The experiences and impact of the COVID-19 pandemic on Young Carers: practice implications and planning for future health emergencies
Hayes, D., Fancourt, D., Burton, A.
10.1101/2023.10.25.23297548 — Posted: 2023-10-26
Changes in emergency department utilization in vulnerable populations after COVID-19 shelter in place orders
Wang, P., Anand, A., Bena, J., Morrison, S., Weleff, J.
10.1101/2023.10.25.23297561 — Posted: 2023-10-26
Inferring community transmission of SARS-CoV-2 in the United Kingdom using the ONS COVID-19 Infection Survey
McCabe, R., Danelian, G., Panovska-Griffiths, J., Donnelly, C. A.
10.1101/2023.10.24.23297454 — Posted: 2023-10-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).